Find out MIVO^® applications and make it your new standard

Breast cancer is the most common cancer in women across most ethnic groups and one of the leading causes of cancer-related deaths worldwide. Mortality is mainly associated with the development of metastases, that is the spreading of tumour cells from the primary site to other parts of the body. MIVO® platform allows to culture fully-humanized breast cancer tissues, eventually in physical contact with a vascular barrier, to monitor and measure the tumour cells migration, spreading, intravasation (i.e. passage across the vascular barrier) and infiltration towards the metastatic site. The circulating tumour cells (CTC) survival under the fluid flow-induced shear stress can be also investigated within MIVO®.

3D tumour model with the proper molecular features that more closely resemble the immunophenotypic variants can be recapitulated in vitro within the MIVO® platform to obtain a clinical-relevant cell culture platform where testing the efficacy of personalized therapeutic approaches and optimize the current and innovative immune-based therapies in a very systematic and reliable way.

The adoption of the MIVO® device is for a functional immune-oncology screening platform but also for cell-based therapies that could be infused into the platform for testing their journey and activity toward tumour cells, like neuroblastoma cancer cells.

3D in vitro cancer models are becoming day-by-day more important as promising alternatives to animal tests for establishing the efficacy of anticancer treatments in vitro. The culture of 3D fully-humanized tumour tissues, such as ovarian tumour models, within an in vivo like fluid-dynamic environment within MIVO®, allows recapitulating the capillary blood flow that feeds the tumour and to properly diffuse drug molecules within the 3D matrix, for more predictive results than static in vitro model.

To know more, read our publication.

Adverse side effects to the heart have become one of the most common causes for preclinical project closures since preclinical models do not fully recapitulate human in vivo dynamics and select the wrong drug. MIVO® organs-on-a-chip technologies allow mimicking the dynamic conditions of the cardiac niche, in terms of flow velocities and shear stress. Both cardiac cell lines, primary cells and cardiac organoids can be hosted within MIVO® chambers under flow conditions. Both tangential and perfusing flow can be properly set up.

These dynamic cardiac models provide a challenging asset for safer and more effective drugs and personalized therapies.

Dermal absorption assays are employed to assess the absorption kinetics of different cosmetic formulations, medical devices and drugs. Depending on the application field (pharmaceutics, cosmetics, toxicology), dermal absorption assays aim to demonstrate the successful delivery of active ingredients, to predict the risks related to the exposure to potentially toxic molecules or to prove the absence of absorption of specific substances classes.

MIVO® is a diffusive chamber compliant with the OECD TG 428 guideline for dermal absorption purposes.

This study highlighted in MIVO® allows the management of artificial skin membranes, human reconstructed tissues or skin biopsies and the easy and fast sampling system allows obtaining dermal absorption kinetics with high automatization and reproducibility.

Human gut physiologically relevant models are requested for more predictive permeation and pharmacokinetic assays.

Through a precise set-up of the physiological fluid flow conditions of the human gut, and a fast and easy multiple sampling of the media, the MIVO® platform can be utilized to evaluate the passage and biodistribution of molecules orally administered, with high predictability and reproducibility. Both CaCO-2 cells monolayers, biomimetic membranes and 3D human intestine tissues can be selected as a gut model and cultured within MIVO chambers, overpassing the limits of the current static in vitro models about the relevant barrier function and molecules diffusion kinetics.

The liver is the organ where each drug and molecule is processed; hence, understanding potential adverse effects are a pivotal part when studying metabolism and toxicology into a drug development process.

Researchers can use our organ on chip MIVO® platform to shape their liver disease models, identify toxicity markers and investigate drug metabolism in vitro.

Tissues continuously undergo the physiological and controlled fluidic flow, that improves mass transports for the proper in vivo like liver tissue feeding and perfusion. Moreover, the MIVO® multi-organ platform supports the fluidic connection of other organs (like gut and kidney) to make it even more predictive on ADME and pharmacokinetic assays.

The development of immunotherapeutic drugs is strictly dependent on the interactions between human cancer and immune cells in a 3D and dynamic environment. Preclinical safety and efficacy assessment of immunotherapies are currently carried out through too simplistic in vitro 2D cell cultures and in vivo xenografts where complete immune compatibility, remains an important challenge.

The combination of tumour models (either 2D or 3D) and fluid-dynamic cells culture within MIVO® improves the relevance of in vitro pre-clinical systems by reproducing the dynamic complex interactions between tumour cells and immune effectors transported in situ via the systemic circulation.